NEW YORK (AP) — Teva Pharmaceutical Industries Ltd.'s fourth-quarter profit sank 34 percent as an acquisition by the world's largest generic drugmaker improved revenue but raised expenses.

The Israeli company said Wednesday its net income dropped to $506 million, or 57 cents per share, in the three months that ended Dec. 31. That compares to $771 million, or 85 cents per share, in the last quarter of 2010.

Excluding a variety of one-time items, like acquisition, amortization and impairment charges, Teva earned $1.59 per share.

Revenue climbed 28 percent to $5.68 billion from $4.41 billion a year ago, topping expectations on Wall Street.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.